Method of isolating and detecting exosomal biomarkers of glioblastoma malignancy
US12228573B2 · kind B2 · utility
0Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2021 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Mar 11, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed herein is a method of diagnosing a malignant glioblastoma. The method can comprise of isolating glioma-derived exosomes from a bodily fluid of the subject, and characterizing the amount of Cluster of Differentiation (CD44) and Cluster of Differentiation 133 (CD133) present in the glioma-derived exosomes. This method allows for the diagnosis of a malignant glioblastoma using CD44 and CD133 levels in EGFRviii specific immunocaptured exosomes from bodily fluids, which has previously not been recognized as providing an indication of a glioblastoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.